CEO: Garth Rapeport

Advent Contact: Shahzad Malik

First-in-class drugs for chronic pulmonary disorders

Respivert developed a pipeline of novel, narrow spectrum, kinase inhibitors, that possessed a unique anti-inflammatory profile, and which were being developed as first-in-class treatments for moderate to severe asthma, COPD and cystic fibrosis.

Advent invested in the Series A in 2007. Respivert was acquired by Centocor Ortho Biotech, a division of Johnson & Johnson in 2010.